

# Discontinuation of continuous renal replacement therapy: A *post hoc* analysis of a prospective multicenter observational study\*

Shigehiko Uchino, MD; Rinaldo Bellomo, MD; Hiroshi Morimatsu, MD; Stanislao Morgera, MD; Miet Schetz, MD; Ian Tan, MD; Catherine Bouman, MD; Ettiene Macedo, MD; Noel Gibney, MD; Ashita Tolwani, MD; Heleen Oudemans-van Straaten, MD; Claudio Ronco, MD; John A. Kellum, MD

**Objectives:** To describe current practice for the discontinuation of continuous renal replacement therapy in a multinational setting and to identify variables associated with successful discontinuation. The approach to discontinue continuous renal replacement therapy may affect patient outcomes. However, there is lack of information on how and under what conditions continuous renal replacement therapy is discontinued.

**Design:** *Post hoc* analysis of a prospective observational study.

**Setting:** Fifty-four intensive care units in 23 countries.

**Patients:** Five hundred twenty-nine patients (52.6%) who survived initial therapy among 1006 patients treated with continuous renal replacement therapy.

**Interventions:** None.

**Measurements and Main Results:** Three hundred thirteen patients were removed successfully from continuous renal replacement therapy and did not require any renal replacement therapy for at least 7 days and were classified as the “success” group and the rest (216 patients) were classified as the “repeat-RRT” (renal replacement therapy) group. Patients in the “success” group had lower hospital mortality (28.5% vs. 42.7%,  $p < .0001$ ) compared with patients in the “repeat-RRT” group. They also had lower creatinine and urea concentrations and a higher urine output at

the time of stopping continuous renal replacement therapy. Multivariate logistic regression analysis for successful discontinuation of continuous renal replacement therapy identified urine output (during the 24 hrs before stopping continuous renal replacement therapy: odds ratio, 1.078 per 100 mL/day increase) and creatinine (odds ratio, 0.996 per  $\mu\text{mol/L}$  increase) as significant predictors of successful cessation. The area under the receiver operating characteristic curve to predict successful discontinuation of continuous renal replacement therapy was 0.808 for urine output and 0.635 for creatinine. The predictive ability of urine output was negatively affected by the use of diuretics (area under the receiver operating characteristic curve, 0.671 with diuretics and 0.845 without diuretics).

**Conclusions:** We report on the current practice of discontinuing continuous renal replacement therapy in a multinational setting. Urine output at the time of initial cessation of continuous renal replacement therapy was the most important predictor of successful discontinuation, especially if occurring without the administration of diuretics. (Crit Care Med 2009; 37:2576–2582)

**KEY WORDS:** acute renal failure; critical illness; continuous renal replacement therapy; epidemiology; hemofiltration; intensive care

Approximately 6% of critically ill patients develop severe acute kidney injury (AKI) and 4% are treated with renal replacement therapy (RRT) (1). Because of hemodynamic stability and steady solute control, continuous RRT (CRRT) is often

the preferred choice over intermittent RRT (IRRT) in the intensive care unit (ICU) (2–4).

Although both CRRT and mechanical ventilation are common organ support therapies in the ICU, there is a gap between the two therapies in terms of

amount and quality of evidence. For mechanical ventilation, there are multiple international epidemiologic studies (5–7), multicenter randomized trials (8–10), and several international consensus guidelines (11–13). For CRRT, on the other hand, there has been only one international epidemiologic study (1) and one consensus set of guidelines (14), although the number of multicenter randomized trials is increasing (15, 16). Therefore, when conducting CRRT, physicians currently have to make decisions about patient care with limited information. In particular, there are negligible data about the process of discontinuation of CRRT. This lack of evidence is different from the field of mechanical ventilation, where many studies dealing with the process of “weaning” from mechanical ventilation have been conducted (17–19).

The BEST Kidney (Beginning and Ending Supportive Therapy for the Kid-

## \*See also p. 2664.

From the Intensive Care Unit (SU), Department of Anesthesiology, Jikei University School of Medicine, Tokyo, Japan; Departments of Intensive Care and Medicine (RB, HM), Austin Hospital, Melbourne, Australia; Department of Nephrology (SM), University hospital Charité, Berlin, Germany; Dienst Intensieve Geneeskunde (MS), Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; Department of Intensive Care Medicine (IT), Singapore General Hospital, Outram Road, Singapore; Adult Intensive Care Unit (CB), Academic Medical Center, Amsterdam, Netherlands; Nephrology Division (EM), University of São Paulo School of Medicine, São Paulo, Brazil; Division of Critical Care Medicine (NG), University of Alberta, Edmonton, Canada; Department of Medicine (AT), Division of Nephrology, University of Alabama at Birmingham, Bir-

mingham, AL; Intensive Care Unit (HO-vS), Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Nephrology - Intensive Care (CR), St. Bortolo Hospital, Vicenza, Italy; Department of Critical Care Medicine (JAK), University of Pittsburgh School of Medicine, Pittsburgh, PA.

This study was supported, in part, by the Austin Hospital Anaesthesia and Intensive Care Trust Fund.

Dr. Gibney holds a consultancy with Gambro. The remaining authors have not disclosed any potential conflicts of interest.

For information regarding this article, E-mail: rinaldo.bellomo@austin.org.au

Copyright © 2009 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

DOI: 10.1097/CCM.0b013e3181a38241

ney) study is a multicentered, multinational, prospective, epidemiologic study for AKI. Its aims are to understand multiple aspects of AKI at an international level (1, 20–24). As part of the BEST kidney study, we sought to investigate the current practice of CRRT discontinuation in a multinational multicenter setting and to identify which factors present at the time of discontinuation may assist physicians in predicting successful cessation of CRRT.

## MATERIALS AND METHODS

This study was conducted by 54 centers in 23 countries from September 2000 to December 2001 (Appendix). The study protocol was reviewed by the Ethics Committees or Investigational Review Boards of each participating site. Because of the anonymous and noninterventional fashion of this study, Ethical Committees in most centers waived the need for informed consent. Where Ethics Committees or Investigational Review Boards required informed consent, we obtained formal written consent. All patients who were treated with CRRT for AKI in one of the participating ICUs during the observational period were considered. From this population, we excluded patients <12 yrs (several units treated older children in their ICU), patients with any dialysis treatment before admission to the ICU, and patients with end-stage renal failure on chronic dialysis.

We developed a case report form for the purpose of the study, and demographic and clinical information was obtained prospectively at study inclusion (1). Additionally, when CRRT was stopped, the following physiologic and laboratory variables were collected: mean arterial pressure, central venous pressure, urine output and diuretics use in 24 hrs before stopping CRRT, need for mechanical ventilation and vasopressors, creatinine, urea, potassium, PaO<sub>2</sub>/Fio<sub>2</sub> ratio, pH, lactate, and mode of CRRT. Reasons why CRRT was stopped were identified from a group of several possible choices (increased urine output, improved metabolic/electrolyte state, improved fluid overload state, decreased urea/creatinine, stable hemodynamics). More than one reason could be selected in each case. The date and time of stopping CRRT were collected and duration from starting CRRT to stopping CRRT was calculated (first CRRT period). Finally, ICU outcomes and hospital outcomes were recorded.

We collected data by means of an electronically prepared Excel-based data collection tool. This was made available to participating centers with instructions. All centers were asked to complete data entry and e-mail the data to the central office. On arrival, all data

were screened in detail by a dedicated intensive care specialist for any missing information, logical errors, insufficient detail, or any other queries. Any queries generated an immediate e-mail inquiry with planned resolution within 48 hrs.

## Data Analysis

To analyze predictive variables for successful discontinuation of CRRT, only patients whose CRRT was stopped were included. Patients who died while they were on CRRT, patients whose treatment was withdrawn, and patients who were transferred to another hospital while still on CRRT were excluded for the analysis. Remaining patients were then divided into two groups according to their RRT requirement within 7 days after the initial discontinuation of CRRT. Patients were placed in the “success” group if they were free from RRT at 7 days after the discontinuation and the rest were in the “repeat-RRT” group. Demographics and variables at discontinuation for these two groups were compared, using the Mann-Whitney *U* test and the Fisher’s exact test. To further analyze relevant factors for successful discontinuation of CRRT, we con-

ducted a multivariate logistic regression analysis with successful discontinuation of CRRT as the dependent variable. All variables presented in Table 1 (demographics of patients and variables at starting CRRT) and Table 2 (patient characteristics at discontinuation of CRRT) were included as dependent variables. Backward stepwise elimination process was used to remove variables if multivariate *p* > .05. Finally, the prediction ability of urine output and serum creatinine concentration for successful discontinuation of CRRT was assessed with the area under the receiver operating characteristic (ROC) curve method (25). We used a commercially available statistical package (StatView, Abacus Concepts, Berkeley, CA). Data are presented as median and interquartile ranges (25<sup>th</sup> to 75<sup>th</sup> percentiles) or percentages. A *p* < .05 was considered statistically significant.

## RESULTS

There were 1006 patients who received CRRT during the study period. Among these patients, 330 died while on CRRT, 12 were transferred to another hospital while on CRRT, and 135 had CRRT withdrawn. These patients were ex-

Table 1. Demographics of study patients and variables at starting continuous renal replacement therapy

	All Patients	Success	Repeat-RRT	<i>p</i>
Number of patients	1006	313	216	
Age, yrs	66 (51–74)	66 (48–74)	64 (50–72)	.69
Male, %	65.8	69.6	67.6	.63
Chronic kidney disease, %	28.1	26.5	39.8	.0017
Surgery, %	45.3	47.3	43.5	.42
SAPS II	48 (39–62)	47 (38–57)	47 (38–58)	.83
Hosp-CRRT, days	5 (1–12)	3 (1–9)	4 (1–12)	.37
Contributing factors to AKI, %				
Sepsis/septic shock	50.2	43.4	48.6	.25
Major surgery	37.6	39.9	38.4	.79
Low cardiac output	26.1	25.4	19.4	.12
Hypovolemia	20.0	20.6	22.2	.67
Drug induced	17.5	16.4	20.4	.25
Hepato-renal syndrome	7.3	6.1	7.9	.48
Obstructive uropathy	2.0	2.6	2.8	>.99
Others	11.4	7.7	8.3	.87
Mechanical ventilation	84.1	77.1	80.5	.39
Vasopressors/inotropes	78.8	76.5	63.3%	.0012
Creatinine, μmol/L	292 (192–427)	300 (190–428)	366 (265–508)	<.0001
Urea (mmol/L)	23 (15–34)	22 (15–32)	27 (18–38)	.0026
Urine output, mL/6 hrs	100 (23–280)	160 (50–390)	100 (29–253)	.0009
Furosemide, mg/6 hrs	60 (0–200)	60 (0–240)	40 (0–180)	.018
Mode of CRRT, %				
CAVHD	0.1	0	0	—
CVVH	52.8	61.3	48.6	.0043
CVVHD	13.1	7.7	13.4	.039
CVVHDF	34.0	31.0	38.0	.11
Intensity, L/hr	2.0 (1.3–2.1)	2.0 (1.4–2.3)	2.0 (1.4–2.1)	.17

RRT, renal replacement therapy; SAPS II, Simplified Acute Physiology Score II; CRRT, continuous renal replacement therapy; Hosp-CRRT, duration between hospital admission and start of CRRT; AKI, acute kidney injury; CAVHD, continuous arteriovenous hemodialysis; CVVH, continuous veno-venous hemofiltration; CVVHD, continuous veno-venous hemodialysis; CVVHDF, continuous veno-venous hemodiafiltration.

**Table 2.** Variables at discontinuation of continuous renal replacement therapy


Variables	Success	Repeat-RRT	<i>p</i>
Number of patients	313	216	
MAP, mm Hg	84 (75–95)	85 (75–98)	.46
CVP, mm Hg	10 (8–13)	10 (7–13)	.79
Vasopressors/inotropes	45.5%	29.5%	.0003
Lactate, mmol/L	1.6 (1.0–2.5)	1.4 (0.9–2.3)	.23
pH	7.43 (7.39–7.48)	7.42 (7.37–7.47)	.023
PO <sub>2</sub> /FIO <sub>2</sub> ratio, torr	274 (215–337)	267 (195–347)	.55
Mechanical ventilation	62.1%	53.8%	.068
Creatinine, μmol/L	151 (102–229)	199 (141–290)	<.0001
Urea, mmol/L	13 (9–18)	15 (11–21)	.0015
Potassium	4.0 (3.7–4.4)	4.1 (3.7–4.4)	.37
Urine output, mL/day	1500 (627–2500)	180 (22–767)	<.0001
Diuretics use	44.9%	24.9%	<.0001
Furosemide, mg/day	0 (0–240)	0 (0–0)	.0001
Other diuretics	4.3%	2.4%	.33
First CRRT period, days	5 (3–9)	8 (4–15)	<.0001
Reasons to stop CRRT, %			
Urine output increased	63.2	19.9	<.0001
Metabolic state improved	49.2	39.8	.039
Fluid overload improved	36.2	31.3	.26
Urea/creatinine decreased	59.0	47.4	.012
Hemodynamically stable	42.7	51.7	.049

RRT, renal replacement therapy; MAP, mean arterial pressure; CVP, central venous pressure; CRRT, continuous renal replacement therapy.

**Table 3.** Outcomes of study patients

Outcomes	All Patients	Success	Repeat-RRT	<i>p</i>
Number of patients	1006	313	216	
ICU LOS, days	12 (5–23)	14 (8–27)	21 (11–34)	.0002
ICU outcome, %				<.0001
Alive off RRT	32.1	82.7	25.7	
Alive on RRT	12.6	0.6	50.9	
Died	55.3	16.7	23.4	
Hospital LOS, days	23 (11–46)	33 (19–61)	42 (25–77)	.0055
Hospital outcome, %				<.0001
Alive off RRT	30.7	70.8	38.9	
Alive on RRT	5.1	0.6	18.5	
Died	64.2	28.5	42.7	

RRT, renal replacement therapy; ICU, intensive care unit; LOS, length of stay.



**Figure 1.** Outcome of patients treated with continuous renal replacement therapy (CRRT). IRRT, intermittent renal replacement therapy.

cluded from further analysis. Among the remaining CRRT patients, 298 were removed successfully from CRRT and did not require RRT until hospital discharge.

Fifteen patients were free from RRT until 7 days after the initial discontinuation of CRRT but required RRT again before hospital discharge. These 313 patients were

classified as the success group and the rest (216 patients) were classified as the repeat-RRT group. The demographics of patients in these two groups are shown in Table 1. Patients in the success group were less likely to have chronic kidney disease (CKD), had lower creatinine and urea, had higher urine volume, and were treated with continuous veno-venous hemofiltration more frequently compared with patients in the repeat-RRT group.

Table 2 shows variables at discontinuation of CRRT. Patients in the success group had lower creatinine and urea concentrations, higher urine output, and were on CRRT for a shorter period before the initial discontinuation compared with patients in the repeat-RRT group. They also had “urine output increased,” “metabolic state improved,” and “urea/creatinine decreased” as the most common reasons for stopping CRRT.

Patient outcomes are shown in Table 3. Hospital mortality for all patients was 64.2%, and 5.1% were still on RRT at hospital discharge. The outcome of these patients over time is shown in Figure 1. For example, 1 wk after starting CRRT, 32.8% had died, 36.6% were still on CRRT, 7.7% had switched to IRRT, and 22.9% had recovered renal function and were free from RRT. Figure 2 shows the outcome of patients who required prolonged RRT. For example, 4 wks after starting CRRT, there were 121 patients who were alive but still required RRT (CRRT or IRRT). The hospital mortality of these patients was 49.6%, and 16.5% of these patients were dialysis dependent at hospital discharge. Patients in the success group had lower ICU and hospital mortality and shorter ICU and hospital length of stay (Table 3).

The multivariable model for successful discontinuation of CRRT showed that the most significant variable was urine output (urine output in the 24 hrs before stopping CRRT: odds ratio, 1.078 per 100 mL/day, *p* < .0001; “urine output increased” as a reason to stop CRRT: odds ratio, 3.097, *p* < 0.0001). Decreased creatinine was also found to be a significant factor (odds ratio, 0.996 per μmol/L change, *p* = .0005).

The area under the ROC curve to predict successful discontinuation of CRRT was 0.808 (0.768–0.844) for urine output and 0.635 (0.586–0.681) for creatinine. Figure 3 shows the impact of diuretics use on the predictive ability of urine output. The area under the ROC curve of urine output for successful discontinuation of CRRT was






Figure 2. Outcome of patients who required prolonged renal replacement therapy (RRT). CRRT, continuous renal replacement therapy.




Figure 3. Impact of diuretics use on predictive ability of urine output. The area under the receiver operating characteristics curve of urine output for successful discontinuation of continuous renal replacement therapy was 0.671 (0.585–0.750) with diuretics and 0.845 (0.799–0.883) without diuretics. Urine output of 436 mL/day for patients without diuretics and of 2330 mL for those with diuretics had the highest accuracy.

0.671(0.585–0.750) with diuretics and 0.845 (0.799–0.883) without diuretics. In the latter ROC curve, a urine output of 436 mL/day without diuretics had the highest sensitivity and specificity. Therefore, the cutoff point of 400 mL/day was chosen to calculate the sensitivity, specificity, positive predictive value, negative predictive value and accuracy, which were 46.5%, 80.9%, 80.9%, 76.5%, and 78.6%, respectively. For patients receiving diuretics, a urine output of 2330 mL had the highest sensitivity and specificity and its positive predictive value (threshold of 2300 mL/day) was 87.9%.

## DISCUSSION

In this study, for the first time, we assessed the worldwide practice for discontinuation of CRRT in the ICU. We found that approximately 50% of patients

treated with CRRT in the ICU had their CRRT stopped, as decided by their attending physician. We also found that urine output at cessation of CRRT was the most important predictor of successful discontinuation of CRRT. However, its predictive ability was affected negatively by the administration of diuretics.

Patients whose CRRT was discontinued successfully had better outcome than patients who needed to be retreated with RRT. The success group had hospital mortality of 28.5%, significantly lower than the repeat-RRT group (42.7%) ( $p < .0001$ ). Patients who require CRRT for AKI have been reported to have a mortality  $>60\%$  (26). Our findings suggest that, once they recover renal function enough to be free from RRT, most patients survive to hospital discharge. When discontinuation of mechanical ventilation fails,

patients often require immediate reintubation and/or prolonged mechanical ventilation. These have been reported to be significantly correlated with higher mortality and morbidity (27, 28). Our study shows that this is also the case for CRRT. It is uncertain whether failure of discontinuation of mechanical ventilation or need for CRRT is just a marker of severity of disease or whether failure itself causes harm to patients. A period without renal support might cause fluid overload, electrolyte abnormalities, and increased uremia. Therefore, it might be better to try to avoid a failed attempt at discontinuation of CRRT in the same way one should seek to avoid a failed extubation.

The only study previously reported in the literature for discontinuation of RRT was conducted by Wu et al (29). Among 304 patients treated with IRRT in their unit, 94 patients (30.9%) did not require RRT for  $>5$  days and 64 of them were free from RRT for  $>30$  days. The independent factors for restarting RRT within 30 days were: longer duration of RRT, higher Sequential Organ Failure Assessment score, oliguria ( $<100$  mL in 8 hrs), and age  $>65$  yrs. There are several differences between their study and ours: number of centers and patients included (94 patients in a single center vs. 529 patients in 54 centers), patient characteristics (postsurgical patients only vs. general ICU patients), mode of RRT (IRRT vs. CRRT), inclusion criteria (patients free from dialysis for  $>5$  days vs. all patients whose CRRT was discontinued), and the definition of successful discontinuation ( $>30$  days vs.  $>7$  days).

Despite these differences between the two studies, urine output at discontinuation of RRT was found to be an important predictor of successful discontinuation in both studies. Diuretics administration, however, negatively affected the predictive ability of urine output. This finding is not surprising because diuretics only increase urine output but not glomerular filtration rate. Nonetheless, if patients make  $>400$  mL/day of urine without diuretics or  $>2300$  mL/day with diuretics, they seem to have a  $>80\%$  chance of successful discontinuation of CRRT. This finding is likely to be of practical utility to clinicians. However, it needs to be tested prospectively in future studies.

Creatinine at discontinuation of CRRT was also found to be a significant variable in our study. This finding is different from that in the study by Wu et al (29).

**Table 4.** Multivariate logistic regression analysis for successful discontinuation of continuous renal replacement therapy

	Odds Ratio (95% CI)	<i>p</i>
Urine output, 100 mL/day	1.078 (1.049–1.108)	<.0001
Urine output increased	3.097 (1.873–5.121)	<.0001
Creatinine, $\mu\text{mol/L}$	0.996 (0.994–0.998)	.0005
Chronic kidney disease	0.534 (0.338–0.844)	.0072
First CRRT period, days	0.969 (0.947–0.993)	.010

CI, confidence interval; CRRT, continuous renal replacement therapy.

This discrepancy might come from the small sample size of the study by Wu et al, as they found significant differences in urea and creatinine between successful weaning and failed weaning from RRT in their univariate analysis. Nevertheless, the predictive ability of creatinine seems to be small (area under the ROC curve <0.7). This is probably because creatinine is lowered by the therapy itself and its value is not related to renal recovery.

We have found that CKD is a strong negative predictor of successful discontinuation of CRRT (odds ratio, 0.534). Wu et al also found that the frequency of CKD was higher in the failed discontinuation group (56.7%) compared with the successful discontinuation group (42.4%), although this difference was not statistically significant ( $p = .27$ ) possibly due to the small sample size. Also, urine output and creatinine level had a stronger association with successful discontinuation of CRRT compared with CKD (Table 4). This observation suggests that, although CKD is an important predictor of successful discontinuation of CRRT, acute variables are likely more important predictors.

Although there were several variables (Table 4) that predicted successful discontinuation of CRRT, only urine output and serum creatinine concentration were measured at the time CRRT was stopped. For mechanical ventilation, many techniques/parameters before extubation have been reported as useful in predicting successful weaning: vital capacity, negative inspiratory force, rapid shallow breathing index, spontaneous breathing trial, and cuff leak test (30). Further studies are needed to identify other parameters, which might assist in correctly predicting successful discontinuation of CRRT.

This study has several limitations. First, centers chose to participate in this study. It is likely, therefore, that there was a self-selection bias toward centers with a particular interest in AKI and its management. These centers might have

managed more AKI patients, treated them more aggressively, made decisions for discontinuing CRRT in different ways and produced different outcomes compared with other institutions. Second, this is an observational study, not a randomized controlled trial. Physicians made decisions to discontinue CRRT according to clinical judgment, not standard predefined criteria. Some CRRT might have been electively switched to IRRT. However, data were collected in 23 countries and this is the first study assessing the current practice of discontinuation of CRRT in the world. As such, it provides the first available glimpse of global practice and outcomes. Finally, it remains unclear whether a better ability to predict successful cessation of CRRT can translate into improved patient-centered outcomes. Also, our findings for the prediction, especially the threshold of urine volume, have not been validated in another external data set. More work is needed to address these issues.

## CONCLUSIONS

In summary, for the first time, we have reported the current practice of discontinuing CRRT in a multinational setting. We found that urine output at the time of initial cessation of CRRT was the most important predictor of successful discontinuation. Diuretics usage, however, negatively affected the predictive ability of urine output. Although a lower creatinine concentration was also related to successful discontinuation of CRRT, its predictive ability was low. Prospective studies are needed to test the success rate of an approach to discontinuation of CRRT based on the urine output cutoff identified in this study.

## REFERENCES

1. Uchino S, Kellum JA, Bellomo R, et al: Acute renal failure in critically ill patients: A mul-

tinational, multicenter study. *JAMA* 2005; 294:813–818

2. Davenport A, Will EJ, Davidson AM: Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. *Crit Care Med* 1993; 21: 328–338
3. Uchino S, Bellomo R, Ronco C: Intermittent versus continuous renal replacement therapy in the ICU: Impact on electrolyte and acid-base balance. *Intensive Care Med* 2001; 27: 1037–1043
4. Silvester W, Bellomo R, Cole L: Epidemiology, management and outcome of severe acute renal failure of critical illness in Australia. *Crit Care Med* 2001; 29:1910–1915
5. Esteban A, Anzueto A, Frutos F, et al: Characteristics and outcomes in adult patients receiving mechanical ventilation: A 28-day international study. *JAMA* 2002; 287: 345–355
6. Vincent JL, Akca S, De Mendonca A, et al: The epidemiology of acute respiratory failure in critically ill patients. *Chest* 2002; 121: 1602–1609
7. Brun-Buisson C, Minelli C, Bertolini G, et al: Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. *Intensive Care Med* 2004; 30:51–61
8. The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342:1301–1308
9. Guerin C, Gaillard S, Lemasson S, et al: Effects of systematic prone positioning in hypoxemic acute respiratory failure: A randomized controlled trial. *JAMA* 2004; 292: 2379–2387
10. National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al: Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 2006; 354: 2564–2575. Epub 2006 May 21
11. Guidelines for standards of care for patients with acute respiratory failure on mechanical ventilatory support. Task Force on Guidelines; Society of Critical Care Medicine. *Crit Care Med* 1991; 19: 275–278
12. Slutsky AS: Consensus conference on mechanical ventilation—January 28–30, 1993 at Northbrook, Illinois, USA. Part I. European Society of Intensive Care Medicine, the ACCP and the SCCM. *Intensive Care Med* 1994; 20:64–79
13. Levy MM, Baylor MS, Bernard GR, et al: Clinical issues and research in respiratory failure from severe acute respiratory syndrome. *Am J Respir Crit Care Med* 2005; 171:518–526. Epub 2004 Dec 10
14. Kellum JA, Mehta RL, Angus DC, et al: The first international consensus conference on

continuous renal replacement therapy. *Kidney Int* 2002; 62:1855–1863

15. Mehta RL, McDonald B, Gabbai FB, et al: A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. *Kidney Int* 2001; 60:1154–1163
16. Vinsonneau C, Camus C, Combès A, et al: Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: A multicentre randomised trial. *Lancet* 2006; 368:379–385
17. Brochard L, Rauss A, Benito S, et al: Comparison of three methods of gradual withdrawal from ventilatory support during weaning from mechanical ventilation. *Am J Respir Crit Care Med* 1994; 150:896–903
18. Esteban A, Frutos F, Tobin MJ, et al: A comparison of four methods of weaning patients from mechanical ventilation. Spanish Lung Failure Collaborative Group. *N Engl J Med* 1995; 332:345–350
19. Esteban A, Alia I, Tobin MJ, et al: Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Spanish Lung Failure Collaborative Group. *Am J Respir Crit Care Med* 1999; 159:512–518
20. Uchino S, Doig GS, Bellomo R, et al: Diuretics and mortality in acute renal failure. *Crit Care Med* 2004; 32:1669–1677
21. Uchino S, Bellomo R, Morimatsu H, et al: External validation of severity scoring systems for acute renal failure using a multinational database. *Crit Care Med* 2005; 33:1961–1967
22. Bagshaw SM, Uchino S, Bellomo R, et al: Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes. *Clin J Am Soc Nephrol* 2007; 2:431–439. Epub 2007 Mar 21
23. Uchino S, Bellomo R, Kellum JA, et al: Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. *Int J Artif Organs* 2007; 30:281–292
24. Uchino S, Bellomo R, Morimatsu H, et al: Continuous renal replacement therapy: A worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. *Intensive Care Med* 2007; 33:1563–1570. Epub 2007 Jun 27
25. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982; 143:29–36
26. Uchino S: The epidemiology of acute renal failure in the world. *Curr Opin Crit Care* 2006; 12:538–543
27. Epstein SK, Ciubotaru RL, Wong JB: Effect of failed extubation on the outcome of mechanical ventilation. *Chest* 1997; 112:186–192
28. Esteban A, Alia I, Gordo F, et al: Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. The Spanish Lung Failure Collaborative

Group. *Am J Respir Crit Care Med* 1997; 156:459–465

29. Wu VC, Ko WJ, Chang HW, et al: Risk factors of early redialysis after weaning from postoperative acute renal replacement therapy. *Intensive Care Med* 2008; 34:101–108. Epub 2007 Aug 15
30. Epstein SK: Decision to extubate. *Intensive Care Med* 2002; 28:535–546

## APPENDIX. Participating Centers and Investigators

**Australia:** Intensive Care Unit, Austin and Repatriation Medical Center (Hiroshi Morimatsu, Rinaldo Bellomo); Department of Intensive Care, Western Hospital (Craig French); Intensive Care Unit, Epworth Foundation (John Mulder); Department of Intensive Care, Sir Charles Gairdner Hospital (Mary Pinder, Brigit Roberts); Intensive Care, Frankston Hospital (John Botha, Pradeen Mudholkar); Critical Care Unit, Flinders Medical Centre (Andrew Holt, Tamara Hunt); **Belgium:** Service de Soins Intensifs, Clinique Saint-Pierre (Patrick Maurice Honoré, Gaetan Clerbaux); Dienst Intensive Geneeskunde, Universitair Ziekenhuis Gasthuisberg (Miet Maria Schetz, Alexander Wilmer); **Czech Republic:** Intensive Care Unit, Department of Internal Medicine I, Charles University Hospital Plzen (Richard Rokyta, Ales Krouzicky); **Germany:** Department of Nephrology, University Hospital Charité, CCM (Stanislao Morgera, Hans-Hellmut Neumayer); Klinik für Anaesthesiologie, Universitätsklinikum Duesseldorf (Kindgen-Milles Detlef, Eckhard Mueller); **Greece:** Intensive Care Unit, General Regional Hospital, “G. Papanikolaou” (Vicky Tsiora, Kostas Sombolos); **Netherlands:** Intensive Care Unit, Onze Lieve Vrouwe Gasthuis (Helena Maria Oudemans-Van Straaten); Adult Intensive Care Unit, Academic Medical Center (Catherine S.C. Bouman, Anne-Cornelie J.M. de Pont); **Israel:** Intermediate Intensive Care Unit, Rambam Medical Center (Yaron Bar-Lavie, Farid Nakhoul); **Italy:** Anesthesia and Intensive Care Unit, Cliniche Humanitas-Gavazzoni (Roberto Ceriani, Franco Bortone); Nephrology - Intensive Care, St. Bortolo Hospital (Claudio Ronco, Nereo Zamperetti); Istituto di Anestesia e Rianimazione Servizio di Anestesia e Rianimazione per la Cardiochirurgia, Ospedale San Raffaele IRCCS Università Vita e Salute (Federico Pappalardo, Giovanni Marino); Unità Operativa di Rianimazione, Ospedale Vittorio Emanuele (Prospero Calabrese, Francesco Monaco); Anestesia e Rianimazione, City Hospital of Sesto San Gio-

vanni (Chiara Liverani, Stefano Clementi); Intensive Care Unit, Surgical and Medical Emergencies Institute (Rosanna Coltrinari, Benedetto Marini); **Norway:** Department of Anesthesia, Rikshospitalet (Jan Frederik Bugge, Fridtjov Ridder-vold); Department of Anaesthesiology, University and Regional Hospital in Tromsø (Paul Åge Nilsen, Joar Julsrud); **Portugal:** Unidade de Cuidados Intensivos (ICU), Hospital de Curry Cabral (Fernando Teixeira e Costa, Paulo Marcelino); Unidade De Cuidados Intensivos Polivalente, Hospital Fernando Fonseca (Isabel Maria Serra); **Russia:** Unit for Extracorporeal Blood Purification, Bakoulev Scientific Center for Cardiovascular Surgery (Mike Yaroustovsky, Rachik Grigoriyanc); **Spain:** Anaesthesiology and Critical Care Department, Hospital Comarcal De Vinaros (Ferran Barrachina, Julio Llorens); Department of Intensive Care Medicine, Section of Severe Trauma, Hospital Universitario “12 de Octubre” (Jose Angel Sanchez-Izquierdo-Riera, Darío Toral-Vazquez); **Sweden:** Dep. of Anesthesia and Intensive Care, Sunderby Hospital (Ivar Wizelius, Dan Hermansson); **Switzerland:** Department of Surgery, Surgery Intensive Care Unit and Departement of Medicine, Medical Intensive Care Unit, University Hospital Zürich (Tomislav Gaspert, Marco Maggiorini); **UK:** Center for Nephrology, Royal Free Hospital (Andrew Davenport); **Canada:** Intensive Care, Maisonneuve-Rosemont Hospital (Martine Leblanc, Lynne Senécal); Division of Critical Care Medicine, University of Alberta, Edmonton (R.T. Noel Gibney, Curtis Johnston, Peter Brindley); **USA:** Department of Critical Care Medicine, University of Pittsburgh Medical Center (Ramesh Venkataraman, John A. Kellum); Department of Medicine, Section of Nephrology, University of Chicago (Patrick Murray, Sharon Trevino); Surgical Intensive Care Unit, Mount Sinai Medical Center (Ernest Benjamin, Jerry Hufanda); Nephrology and Hypertension - M82, Cleveland Clinic Foundation (Emil Paganini); Department of Medicine, Division of Nephrology, University of Alabama at Birmingham (Ashita Tolwani, David Warnock); Internal Medicine/ Nephrology, University of Nebraska Medical Center (Nabil Guirguis); **Brazil:** Nephrology Division, University of São Paulo School of Medicine (Luis Yu, Etienne V. Macedo); Nephrology Division, do Hospital Servidor Público Estadual de São Paulo (Sandra Maria Rodrigues Laranja, Cassio José Rodrigues); Nephrol-

ogy Unit, Casa de Saúde São José/CDR Serviços Hospitalares (José Hermógenes Rocco Suassuna, Frederico Ruzany); Lutheran University of Brasil (Bruno Campos, Jayme Burmeister); **Uruguay:** Department of Critical Care Medicine, Impasa (Raúl Lombardi, Teresita Llopert); **China:** Intensive Care Unit, Department of Anesthesia, Pamela Youde Nethersole Eastern Hospital (Ian K.S. Tan); Surgical Intensive Care Unit, Beijing Chao Yang Hospital (Hui De Chen, Li Wan); **Indonesia:** ICU, National Cardiovascular Center and Mitra Keluarga Hospital (Iqbal Mustafa, Iwayan Suranadi); **Japan:** Intensive Care Center, Teikyo University School of Medicine Ichihara Hospital (Nobuo Fuke, Masaaki Miyazawa); Intensive Care Unit, Okayama University Hospital (Hiroshi Katayama, Toshiaki Kurasako); Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University (Hiroyuki Hirasawa, Shigeto Oda); Emergency and Critical Care Medicine, Fukuoka University Hospital (Koichi Tanigawa, Keiichi Tanaka); **Singapore:** Medicine Department, National University of Singapore (Kang Hoe Lee); Surgical Intensive Care Unit, Tan Tock Seng Hospital (Shi Loo, Kulgit Singh).